{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:45:59Z","timestamp":1791218759055,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.ejca.2010.03.039","type":"journal-article","created":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T06:22:04Z","timestamp":1274077324000},"page":"2206-2215","source":"Crossref","is-referenced-by-count":95,"title":["Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)"],"prefix":"10.1016","volume":"46","clinical-trial-number":[{"clinical-trial-number":"2006-004529-27","registry":"10.18810\/euctr"}],"author":[{"given":"Patrick","family":"Sch\u00f6ffski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"De Greve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pascal","family":"Machiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Wolter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Munzert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertraud","family":"Hanft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Rapion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Allgeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bogaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2010.03.039_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1634\/theoncologist.2009-0010","article-title":"Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology","volume":"14","author":"Sch\u00f6ffski","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2010.03.039_bib2","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1535-7163.MCT-06-0781","article-title":"Regulation of mitosis via mitotic kinases: new opportunities for cancer management","volume":"6","author":"Schmit","year":"2007","journal-title":"Mol Cancer Therapy"},{"key":"10.1016\/j.ejca.2010.03.039_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc1841","article-title":"Targeting polo-like kinase 1 for cancer therapy","volume":"6","author":"Strebhardt","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"Suppl S2","key":"10.1016\/j.ejca.2010.03.039_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cub.2006.12.037","article-title":"BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo","volume":"17","author":"Steegmaier","year":"2007","journal-title":"Curr Biol"},{"key":"10.1016\/j.ejca.2010.03.039_bib5","doi-asserted-by":"crossref","first-page":"8115","DOI":"10.1200\/jco.2008.26.15_suppl.8115","article-title":"A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl 18","key":"10.1016\/j.ejca.2010.03.039_bib6","first-page":"88s","article-title":"A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors","volume":"24","author":"Hofheinz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.03.039_bib7","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1200\/JCO.2008.16.1547","article-title":"Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors","volume":"26","author":"Mross","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2010.03.039_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.03.039_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Controlled Clin Trials"},{"key":"10.1016\/j.ejca.2010.03.039_bib10","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1200\/jco.2008.26.15_suppl.8030","article-title":"Randomized phase II trial of two dosing schedules of BI 2536, a novel Plk-1 inhibitor, in patients with relapsed advanced or metastatic non-small-cell lung cancer (NSCLC)","volume":"26","author":"Von Pawel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.03.039_bib11","doi-asserted-by":"crossref","first-page":"14547","DOI":"10.1200\/jco.2008.26.15_suppl.14547","article-title":"An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)","volume":"26","author":"Pandha","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.03.039_bib12","unstructured":"Mross K, Dittrich C, Aulitzky WE, et al. A randomized phase II trial of the novel polo-like kinase 1 inhibitor BI 2536 in chemona\u00efve patients with unresectable advanced pancreatic cancer\u2014a study in cooperation with the CESAR network of investigators. In: Presented at the 33rd annual congress of the European Society for Medical Oncology, September 12\u201316, 2008, Stockholm, Sweden."},{"key":"10.1016\/j.ejca.2010.03.039_bib13","unstructured":"Sch\u00f6ffski P, Awada A, Dumez H, et al. A phase I single dose escalation study of the novel polo-like kinase I inhibitor BI 6727 in patients with advanced solid tumors. In: Presented at the 20th European Organization for Research and Treatment of Cancer \u2013 National Cancer Institute \u2013 American Association for Cancer Research symposium on molecular targets and cancer therapeutics, October 21\u201324, 2008, Geneva, Switzerland."},{"issue":"9","key":"10.1016\/j.ejca.2010.03.039_bib14","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","article-title":"BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity","volume":"15","author":"Rudolph","year":"2009","journal-title":"Clin Can Res"},{"key":"10.1016\/j.ejca.2010.03.039_bib15","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/jco.2008.26.15_suppl.2515","article-title":"Phase I study of ON 01910.Na, a novel polo-like kinase 1 pathway modulator, administered as a weekly 24-h continuous infusion in patients with advanced cancer","volume":"26","author":"Weinstein","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.03.039_bib16","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-06-0214","article-title":"A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with Polo-like kinase-1-interacting properties, in patients with advanced solid tumors","volume":"12","author":"Garland","year":"2006","journal-title":"Clin Can Res"},{"issue":"Suppl 14","key":"10.1016\/j.ejca.2010.03.039_bib17","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/jco.2004.22.14_suppl.3034","article-title":"A phase I and pharmacokinetic study of HMN-214, a novel oral Polo-like kinase inhibitor, in patients with advanced solid tumors","volume":"22","author":"Von Hoff","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.03.039_bib18","doi-asserted-by":"crossref","unstructured":"Blagden S, Olmos D, Sharma R, et al. A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors. In: Presented at the 20th European Organization for Research and Treatment of Cancer \u2013 National Cancer Institute \u2013 American Association for Cancer Research symposium on molecular targets and cancer therapeutics, October 21\u201324, 2008, Geneva, Switzerland.","DOI":"10.1016\/S1359-6349(08)72365-6"},{"key":"10.1016\/j.ejca.2010.03.039_bib19","unstructured":"Chapman CM, Perez-Galan P, Wiestner A. ON 01910.Na, a novel clinical grade PLK-1 inhibitor, selectively induces apoptosis in human B-cell chronic lymphocytic leukemia (B-CLL). In: Presented at the American Association of Cancer Research 2009 annual meeting, April 18\u201322, 2009, Denver, CO."},{"key":"10.1016\/j.ejca.2010.03.039_bib20","first-page":"514","article-title":"HMN-214, a novel oral antimicrotubular agent, inhibitor of Polo-like-and cyclin-dependent kinases: clinical, pharmacokinetic (PK), pharmacodynamic (PD) relationships observed in a phase I trial of a daily\u00d75 schedule every 28 days","volume":"22","author":"Patnaik","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 18","key":"10.1016\/j.ejca.2010.03.039_bib21","doi-asserted-by":"crossref","first-page":"13137","DOI":"10.1200\/jco.2006.24.18_suppl.13137","article-title":"Phase I study of ON 01910.Na by 3-day continuous infusion (CI) in patients (pts) with advanced cancer","volume":"24","author":"Ohnuma","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 18","key":"10.1016\/j.ejca.2010.03.039_bib22","doi-asserted-by":"crossref","first-page":"13026","DOI":"10.1200\/jco.2006.24.18_suppl.13026","article-title":"Phase I study of ON 01910.Na, a novel cell cycle inhibitor in adult patients with solid tumors","volume":"24","author":"Donehower","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910003011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910003011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T18:41:24Z","timestamp":1591296084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910003011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0959804910003011"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.03.039","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}